lundi 15 octobre 2018

Onco Actu du 15 octobre 2018

1. Biologie

Study signals a limit to cancer’s complexity [Harvard Gazette]

Biology Week 2018: the scientists studying what makes cancer tick [Institute of Cancer Research]

3.1 Prévention - Tabac

Report: No Surge in Illicit Cigarette Seizures after Menthol Ban [ACS]

3.1.1 Prévention - Tabac - e-cigs

FDA investigating whether dozens of e-cigarette products are being illegally marketed [Washington Post]

FDA advances investigation into whether more than 40 e-cigarette products are being illegally marketed and outside agency's compliance policy [FDA]

4.1 Dép., diag. & prono. - Prostate

How celebrities like Stephen Fry advocating prostate cancer testing could do more harm than good [Independent]

4.12 Biopsies liquides

Blood Test Identifies More Treatable Cancer Mutations Than Tissue Biopsy Alone [Penn Medicine]

4.2 Dép., diag. & prono. - Génome

Researchers find a ‘critical need’ for whole genome sequencing of young cancer patients [St. Jude Children's Research Hospital]

Roche launches NGS AVENIO Tumor Tissue Analysis Kits for oncology research [Roche]

4.9 Dép., diag. & prono. - Sein

Can Artificial Intelligence Help Reduce False-positive Mammograms? [Cancer Research Catalyst]

Thermography is Not Approved for Breast Cancer Screening in Canada [Science-Based Medicine]

5.12.4 Immunothérapies - Essais

Bristol Stumbles in Lung Cancer Again as Rivals Play Catch-Up [Xconomy]

Bristol-Myers stumbles in lung cancer quest as I-O star Opdivo flunks small cell trial [FiercePharma]

Bristol-Myers concedes a PhIII lung cancer flop for Opdivo as competition heats up in SCLC [EndPoints]

Bristol-Myers' Opdivo fails to meet lung cancer study goal [Reuters]

Bristol-Myers Squibb Announces Phase 3 CheckMate -331 Study Does Not Meet Primary Endpoint of Overall Survival with Opdivo Versus Chemotherapy in Patients with Previously Treated Relapsed Small Cell Lung Cancer [BMS]

5.2 Pharma

Roche’s Kadcyla reduced the risk of disease recurring in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment [Roche]

5.3 Traitements - FDA, EMA, NICE...

MHRA Offers Guidance for Trials in Event of ‘No-Deal’ Brexit [RAPS]